GSK and Alamar Biosciences Partner on Precision Prevention Research
What happened
GSK and Alamar Biosciences announced a strategic scientific collaboration to advance precision prevention. The partnership will use Alamar's NULISAseq Immune 340 and NULISAseq Neuro 220 panels in a large-scale study. This research will analyze over 60,000 serum samples to examine how circulating protein signatures relate to disease progression and treatment response across respiratory, liver, kidney, neurological, and autoimmune conditions.
From finanznachrichten.de
Why it matters
The collaboration aims to generate deep proteomic insights to advance precision prevention, treatment, and earlier disease detection in real-world health care settings. By identifying protein signatures that better distinguish underlying biological differences, the research seeks to improve how diseases are classified and treated.
From finanznachrichten.de
Who's involved
- GSKBritish multinational pharmaceutical and biotechnology company collaborating on precision prevention research
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company